Edwards Lifesciences shares rose 3.4% this evening to a price of $77.76. The stock is still trading within range of its average target price of $77.65, and over the last 52 weeks, it has recorded a 2.3% performance. Analysts have given the large-cap Specialty Industrial Machinery stock target prices ranging from $57.0 to $96.0 dollars per share, with an average rating of buy.
The stock has a very low short interest at 1.7%, and a short ratio of 2.26. The company's insiders own 0.84% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 85.0% of Edwards Lifesciences's shares being owned by this investor type.
Institutions Invested in Edwards Lifesciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Vanguard Group Inc | 9% | 51,633,416 | $4,015,014,538 |
| 2023-09-30 | Blackrock Inc. | 8% | 51,375,446 | $3,994,954,790 |
| 2023-09-30 | Capital International Investors | 5% | 30,253,728 | $2,352,529,953 |
| 2023-09-30 | State Street Corporation | 4% | 26,447,736 | $2,056,576,007 |
| 2023-09-30 | Alliancebernstein L.P. | 4% | 22,741,712 | $1,768,395,573 |
| 2023-09-30 | Bank Of New York Mellon Corporation | 3% | 17,608,841 | $1,369,263,513 |
| 2023-09-30 | Wellington Management Group, LLP | 3% | 16,434,401 | $1,277,939,056 |
| 2023-09-30 | Brown Advisory Inc. | 2% | 15,133,146 | $1,176,753,465 |
| 2023-09-30 | Geode Capital Management, LLC | 2% | 12,691,799 | $986,914,317 |
| 2022-12-31 | Norges Bank Investment Management | 1% | 8,824,423 | $686,187,151 |
Besides an analyst consensus of little upside potential, other market factors point to there being mixed market sentiment on Edwards Lifesciences.
